Currently valproic acid is considered to be the drug of first choice for juvenile myoclonic epilepsy (JME) resulting in a 70-90% control rate for all seizure types associated with JME. In those situations where valproic acid fails to control seizure activity, results in unacceptable side-effects, or is declined due to potential side-effects, an alternative effective monotherapy would be desirable. Five adolescent female patients were placed on methsuximide for JME. All five patients have been seizure free with the use of methsuximide and four out of five are now on methsuximide monotherapy with good success. C.L. has now had complete seizure control on methsuximide monotherapy, a total of 1200 mg a day, for 7 years with the exception of one seizure event occurring on an attempted discontinuation of methsuximide after being 5 years seizure free. Methsuximide monotherapy as demonstrated in these five patients is an effective treatment for JME.
INTRODUCTION
Juvenile myoclonic epilepsy (JME) is an epileptic syndrome which in most cases has the onset during adolescence of the following three seizure types: (1) myoclonic jerks, frequently bilateral involving both arms, predominantly seen upon awakening in the morning; (2) tonic clonic events frequently in association with myoclonic jerks; and (3) infrequent absence episodes ~-5. Prior to the introduction of valproic acid for the treatment of JME, a variety of other medications were used with only partial Success 6"7. With the introduction of valproic acid a high percentage, approximately 70-90%, of patients with JME have seizure control 3"8. Some patients fail to have their seizures controlled related to side effects from valproic acid 9. Particularly in adolescent females, weight gain may be a problem with valproic acid resulting in its discontinuation ~°. When valproic acid monotherapy fails to achieve complete seizure control, other anticonvulsants may be added in a two drug combination. Methsuximide presents a unique anticonvulsant profile which potentially would allow for the treatment of JME in monotheraphy. Methsuximide is known to treat all three seizure types seen in JME ~ ~-~3. Five patients are presented who have had methsuximide used in monotherapy for the treatment of JME.
METHOD
All medical records in the Texas Tech University Health Sciences Center Neurology Clinic were reviewed for a diagnosis of JME and treatment with methsuximide. This was a retrospective review covering a period of nine years. Inclusion criteria for the diagnosis of JME were typical case histories, an established clinical diagnosis of JME, and supportive EEG data. Supportive EEG data included (1) normal background activity, and (2) generalized polyspike-wave complexes, (3) 4-6 Hz generalized spike wave activity, (4) 3 Hz generalized spike wave activity, or (5) irregular spike wave complexes.
RESULTS
Five females with JME on methsuximide were identified. Four out of the five are currently on methusximide monotheraphy. One individual is on treatment with valproic acid in addition to methsuximide, but in the past had been treated successfully with methsuximide monotherapy. The therapeutic approach was changed in this individual due to a complaint of sedation. The patient felt the combination of valproic acid, which failed in monotherapy, with methsuximide gave satisfactory seizure control with fewer side-effects. These five patients are being continued on methsuximide long-term (see Table 1 ). At this time all five patients are under good seizure control.
CASE HISTORY
C.L. is now a 22-year-old female. She was first seen at the age of 13 years for a history of having had two tonic-clonic seizure events lasting approximately 5 minutes each. Her initial seizure manifestation occurred 3 months earlier, at which time she was noted to have bilateral jerks of her arms in the morning which caused her to drop whatever she was holding. She was described as alert and able to talk during these episodes. Her second tonic-clonic seizure, occurring 2 days prior to her initial evaluation, was preceded by bilateral arm jerks during which she stated, 'Oh, Mom, I can't stop them from shaking' and then proceeded directly into a tonic-clonic seizure. The patient's past medical history was unremarkable. Family history was significant for a 20-yearold female sibling with epilepsy. Review of systems was otherwise unremarkable. Her neurologic examination was normal. An EEG was obtained and showed a generalized spike wave discharge at 5 Hz. A CT scan with and without contrast was normal. She was given a diagnosis of JME and methsuximide, 750mg per day, was started. This resulted in a normethsuximide level of 16/zg/ml; therapeutic range 10-40/zg/ml. When a few further myoclonic jerks were noted, the dosage was increased to 1200mg a day, resulting in a normethsuximide level of 30/,tg/ml. After five years of complete seizure control on methsuximide, a follow up EEG was obtained which was normal and the patient began a slow taper off methsuximide. After being completely off methsuximide for two weeks, the patient had a tonic clonic seizure lasting approximately 30 seconds. The patient denied any illness at the time of the seizure but reported the increased stress of final exams. The methsuximide was restarted at 1200mg a day and the patient has been completely seizure free since that time (for 2 years). Current plans are to continue the methsuximide as prescribed for an indefinite time period.
DISCUSSION
Methsuximide is primarily considered a second line anticonvulsant for absence epilepsy because ethosuximide is more effective than methsuximide in the treatment of absence seizures t4. Methsuximide, however, has a wider spectrum of anti-seizure activity than ethosuximide'~"2 Methsuximide is an effective adjunctive therapy for other generalized epilepsies, particularly in combination with valproic acid ~5. Methsuximide has also been documented to be successful in controlling myoclonic epilepsy or myoclonic atonic seizures in some patients ~3't~'~7.
Valproic acid is the only currently marketed anticonvulsant which is considered both safe and effective in controlling all the individual seizure types, namely, generalized tonic-clonic, myoclonic, and absence seizures seen in JME ~s-2°. Therefore, it is not surprising that valproic acid has been found to be an effective treatment for JME as an epilepsy syndrome 2'. Those anticonvulsants which treat partial and tonic-clonic seizures alone fail to address the myoclonic and absence components of JME. Likewise those medications, such as clonazepam and trimethadione, which treat absence and myoclonic seizures but do not control primary generalized tonic clonic seizures, are not effective as monotherapy 2''22. An additional effective medication for treatment of JME, either in monotherapy or as an adjunctive to valproic acid would be very desirable. Currently no series has been published which has used methsuximide as monotherapy for the treatment of JME. The five patients presented with JME all have shown good responses to treatment with methsuximide resulting in complete seizure control on monotherapy in four out of five without significant side-effects As demonstrated in C.L., methsuximide both can and did result in long term seizure control. The benefit in C.L. to methsuximide was readily demonstra'ted when she had a generalized but short tonic-clonic seizure 2 weeks off of treatment. Patient 1 initially presented with only myoclonic jerks and was treated with clonazepam with good control of myoclonic episodes but not of subsequent tonicclonic events. When offered a treatment choice between methsuximide and valproic acid, the patient and her family elected to use methsuximide over valproate due to concerns about potential side effects. Patient 2 was initially started on valproic acid which failed to completely control the patient's seizures resulting in a change to treatment with methsuximide. The patient was controlled on methsuximide monotherapy but complained about mild sedation. She requested a reduction in her dose and myoclonic seizure activity returned. The patient then elected to use a combination of valproic acid and methsuximide in the hope that lower doses of both medications would be able to control her seizures in combination without side-effects. Patient 4 was initially treated with valproic acid but she discontinued on her own the valproic acid due to weight gain and multiple other complaints to include headaches and dizziness. She was started on methsuximide with resulting good seizure control. Patient 5 was started on valproic acid, but due to weight gain and hair loss, she requested a change of medication. She was switched to felbamate but subsequently was withdrawn due to concerns about serious idiosyncratic side-effects and a previous history of idiopathic thrombocytopenia. The patient is currently using methsuximide with no clinical side-effects.
In JME methsuximide can be used as an effective alternative monotherapy to valproic acid. Individual patients may even prefer methsuximide over valproic acid for treatment of JME, as did C.L. Methsuximide is currently an available and marked anticonvulsant and presents an acceptable side-effect risk profile for use in JME 23. Other adjuncts to valproic acid for JME (primidone, phenytoin, ethosuximide, or felbamate) cannot be used as monotherapy without a risk of unacceptable side-effects 24.
